Market closed

Kiniksa Pharmaceuticals/KNSA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

Ticker

KNSA
Trading on

Industry

Biotechnology

Employees

297

KNSA Metrics

BasicAdvanced
$1.9B
Market cap
-
P/E ratio
-$0.15
EPS
0.38
Beta
-
Dividend rate
$1.9B
0.38
$27.92
$14.12
424K
3.571
2.838
2.141
2.621
-3.35%
-2.42%
5.529
4.34
4.51
61.822
20.69%
-104.58%
253.02%
-62.42%

What the Analysts think about KNSA

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Kiniksa Pharmaceuticals stock.

KNSA Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

KNSA Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy KNSA

$

Sign up or log in to buy
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Kiniksa Pharmaceuticals stock?

Kiniksa Pharmaceuticals (KNSA) has a market cap of $1.9B as of October 12, 2024.

What is the P/E ratio for Kiniksa Pharmaceuticals stock?

The price to earnings (P/E) ratio for Kiniksa Pharmaceuticals (KNSA) stock is 0 as of October 12, 2024.

Does Kiniksa Pharmaceuticals stock pay dividends?

No, Kiniksa Pharmaceuticals (KNSA) stock does not pay dividends to its shareholders as of October 12, 2024.

When is the next Kiniksa Pharmaceuticals dividend payment date?

Kiniksa Pharmaceuticals (KNSA) stock does not pay dividends to its shareholders.

What is the beta indicator for Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals (KNSA) has a beta rating of 0.38. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.